HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Stock indexes in the U.S. moved upward Wednesday as the gained 1.14%. Meanwhile, the increased 0.78%, and the rose 0.61%.

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced plans to expand into Canada with a weight-loss solution ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why I rate HIMS stock a Strong Buy.

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

Hot telehealth stock Hims & Hers Health (NYSE: HIMS) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high. Yet Hims & Hers is still up nearly ...